InterCure Ltd. (INCR), operating under the Canndoc brand, has secured NIS 22 million (approximately US$7.4 million) in new funding via a private placement. The capital will support the company’s recovery, expand its production capacity, and pursue growth opportunities in regulated medical‑cannabis markets, notably Israel, Germany and other key jurisdictions.
The financing includes commitments from existing shareholders, Chief Executive Officer Alexander Rabinovich, and leading pharma‑focused hedge funds such as Bennu Pharma Fund Ltd., managed by Ori Hershkovitz. If all warrants issued in the placement are exercised, total funding could rise to NIS 54 million (≈US$18.6 million).
Under the placement terms, InterCure will issue 7,895,143 ordinary shares at a price of NIS 2.75 per share (≈US$0.94), representing a premium to the NIS 2.69 closing price on the Tel Aviv Stock Exchange as of June 17 2026. Investors will also receive warrants to purchase an additional 7,895,143 shares at an exercise price of NIS 4.125 per share (≈US$1.41), a 53 % premium to the reference price, exercisable for five years. The transaction remains subject to definitive documentation and certain closing conditions, including shareholder approval for Mr. Rabinovich’s participation and applicable transfer restrictions.
Rabinovich described the financing as a critical step in InterCure’s recovery and growth strategy, highlighting confidence from both existing shareholders and institutional investors. He indicated that the proceeds will fund expansion of the Nir Oz facility, meet rising demand in Israel and international markets, and accelerate global expansion, particularly in Germany and other regulated medical‑cannabis regions.
In addition, anticipated compensation for war‑related damages, combined with the new capital, is expected to strengthen the balance sheet and support a return to sustainable growth and profitability.
The securities have not been registered under the U.S. Securities Act and may not be sold in the United States unless registered or an exemption applies.
Over the past year, INCR’s share price has ranged from $0.68 to $1.77. The stock closed Monday at $1.09, up 17.37 %, and was trading at $1.00 in after‑hours sessions, down 8.26 %.
Also Read
- As Vance Leads Iran Negotiations, Trump Creates Disruptions in His Path
- Lean Hog Futures Slip Amid Growing Managed Money Short Positions
- A Decade of Brexit: How the Promise of Sovereignty Left Britain Searching for Answers]
- Honoring 250 Years of Employee Ownership: A Parallel Milestone to America’s Semiquincentennial